Literature DB >> 15507617

Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Drew L Lichtenstein1, Konstantin Doronin, Karoly Toth, Mohan Kuppuswamy, William S M Wold, Ann E Tollefson.   

Abstract

Adenoviruses (Ads) encode several proteins within the early region 3 (E3) transcription unit that help protect infected cells from elimination by the immune system. Among these immunomodulatory proteins, the receptor internalization and degradation (RID) protein complex, which is composed of the RIDalpha (formerly E3-10.4K) and RIDbeta (formerly E3-14.5K) subunits, stimulates the internalization and degradation of certain members of the tumor necrosis factor (TNF) receptor superfamily, thus blocking apoptosis initiated by Fas and TNF-related apoptosis-inducing ligand (TRAIL). The experiments reported here show that TRAIL receptor 2 (TR2) is cleared from the cell surface in Ad-infected cells. Virus mutants containing deletions that span E3 were used to show that the RID and E3-6.7K proteins are both necessary for the internalization and degradation of TR2, whereas only the RID protein is required for TRAIL receptor 1 downregulation. In addition, replication-defective Ad vectors that express individual E3 proteins were used to establish that the RID and E3-6.7K proteins are sufficient to clear TR2. These data demonstrate that E3-6.7K is an important component of the antiapoptosis arsenal encoded by the E3 transcription unit of subgroup C Ads.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507617      PMCID: PMC525093          DOI: 10.1128/JVI.78.22.12297-12307.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  The adenovirus E3-6.7K protein adopts diverse membrane topologies following posttranslational translocation.

Authors:  Alexander R Moise; Jason R Grant; Roger Lippé; Reinhard Gabathuler; Wilfred A Jefferies
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Preparation and titration of CsCl-banded adenovirus stocks.

Authors:  Ann E Tollefson; Mohan Kuppuswamy; Elena V Shashkova; Konstantin Doronin; William S M Wold
Journal:  Methods Mol Med       Date:  2007

3.  The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis.

Authors:  J Shisler; C Yang; B Walter; C F Ware; L R Gooding
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells.

Authors:  A E Tollefson; T W Hermiston; D L Lichtenstein; C F Colle; R A Tripp; T Dimitrov; K Toth; C E Wells; P C Doherty; W S Wold
Journal:  Nature       Date:  1998-04-16       Impact factor: 49.962

5.  Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2.

Authors:  C A Benedict; P S Norris; T I Prigozy; J L Bodmer; J A Mahr; C T Garnett; F Martinon; J Tschopp; L R Gooding; C F Ware
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

6.  Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.

Authors:  T Dimitrov; P Krajcsi; T W Hermiston; A E Tollefson; M Hannink; W S Wold
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

8.  The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization.

Authors:  A Elsing; H G Burgert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  Two distinct transport motifs in the adenovirus E3/10.4-14.5 proteins act in concert to down-modulate apoptosis receptors and the epidermal growth factor receptor.

Authors:  Annette Hilgendorf; Johan Lindberg; Zsolt Ruzsics; Stefan Höning; Andreas Elsing; Madelaine Löfqvist; Hartmut Engelmann; Hans-Gerhard Burgert
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

Review 10.  Viruses and the TNF-related cytokines, an evolving battle.

Authors:  Chris A Benedict
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

View more
  17 in total

1.  Open reading frame E3-10.9K of subspecies B1 human adenoviruses encodes a family of late orthologous proteins that vary in their predicted structural features and subcellular localization.

Authors:  Kathryn M Frietze; Samuel K Campos; Adriana E Kajon
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

2.  Identification of a novel immunosubversion mechanism mediated by a virologue of the B-lymphocyte receptor TACI.

Authors:  Jason R Grant; Alexander R Moise; Wilfred A Jefferies
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

3.  Homologous recombination in E3 genes of human adenovirus species D.

Authors:  Gurdeep Singh; Christopher M Robinson; Shoaleh Dehghan; Morris S Jones; David W Dyer; Donald Seto; James Chodosh
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Genomic characterization of human adenovirus type 4 strains isolated worldwide since 1953 identifies two separable phylogroups evolving at different rates from their most recent common ancestor.

Authors:  Gabriel Gonzalez; Camden R Bair; Daryl M Lamson; Hidemi Watanabe; Laura Panto; Michael J Carr; Adriana E Kajon
Journal:  Virology       Date:  2019-09-08       Impact factor: 3.616

5.  A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.

Authors:  Changyu Zheng; Ana P Cotrim; Nikolay Nikolov; Fumi Mineshiba; William Swaim; Bruce J Baum
Journal:  Hum Gene Ther Methods       Date:  2012-07-20       Impact factor: 2.396

6.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

7.  Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex.

Authors:  Y Rebecca Chin; Marshall S Horwitz
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

Authors:  E V Shashkova; M N Kuppuswamy; W S M Wold; K Doronin
Journal:  Cancer Gene Ther       Date:  2007-11-09       Impact factor: 5.987

9.  TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.

Authors:  Ching-Huang Wu; Ching-Hai Kao; Ahmad R Safa
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

Review 10.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.